Skip to main content
OpenTrials

Clinical trial condition

Neoplasms, Plasma Cell

Explore clinical trials studying Neoplasms, Plasma Cell. Study availability and eligibility vary by location and protocol.

2,604 public trials 547 recruiting studies
Refine in advanced search Browse all conditions

Neoplasms, Plasma Cell trial results

Completed

Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma

NCT00932698

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • H. Lee Moffitt Cancer Center Tampa, Florida, United States
  • Emory University Atlanta, Georgia, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States
View Trial Details
Completed

Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

NCT01001442

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Emory University Winship Cancer Institute Atlanta, Georgia, United States
  • The University of Chicago Chicago, Illinois, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Roswell Park Cancer Institute Buffalo, New York, United States
View Trial Details
Completed

BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma

NCT01638936

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • City of Hope Duarte, California, United States
  • USC Norris Comprehensive Cancer Center Los Angeles, California, United States
  • Mayo Clinic Jacksonville, Florida, United States
  • Memorial Healthcare System Pembroke Pines, Florida, United States
View Trial Details
Completed

Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma

NCT02046070

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Hazard, Kentucky, United States
  • Boston, Massachusetts, United States
  • Rochester, Minnesota, United States
  • St Louis, Missouri, United States
View all 24 locations
View Trial Details
Completed

Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients

NCT02159365

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Acrc/Arizona Clinical Research Center, Inc. Tucson, Arizona, United States
  • Highland Oncology Group Fayetteville, Arkansas, United States
  • Comprehensive Blood And Cancer Center Bakersfield, California, United States
  • California Cancer Associates for Research and Excellence Encinitas, California, United States
View all 29 locations
View Trial Details
Completed

Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas

NCT01282424

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +30 more
Locations
  • St. Jude Medical Center Fullerton, California, United States
  • Pacific Shores Medical Group Long Beach, California, United States
  • UCLA Los Angeles, California, United States
  • Central Coast Medical Oncology Santa Maria, California, United States
View all 41 locations
View Trial Details

Related conditions